Recombinant	JJ	recombinant JJ PennPOS
human	JJ	human JJ PennPOS
serum-amyloid-P	NN	serum-amyloid-P NN PennPOS
in	IN	in IN PennPOS
healthy	JJ	healthy JJ PennPOS
volunteers	NNS	volunteer NNS PennPOS
and	CC	and cc NUPOS
patients	NNS	patient NNS PennPOS
with	IN	with pp NUPOS
pulmonary	JJ	pulmonary JJ PennPOS
fibrosis	NN	fibrosis NN PennPOS
.	.	. . NUPOS

PRM-151	NN	PRM-151 NN PennPOS
,	,	, , NUPOS
recombinant	JJ	recombinant JJ PennPOS
human	JJ	human JJ PennPOS
Pentraxin-2	NN	Pentraxin-2 NN PennPOS
(	(	( ( NUPOS
PTX-2	NN	PTX-2 NN PennPOS
)	)	) ) NUPOS
also	RB	also av NUPOS
referred	VBD	refer VBD PennPOS
to	TO	to p-acp NUPOS
as	IN	as c-acp NUPOS
serum-amyloid-P	NN	serum-amyloid-P NN PennPOS
(	(	( ( NUPOS
SAP	NN	sap NN PennPOS
)	)	) ) NUPOS
,	,	, , NUPOS
is	VBZ	be vbz NUPOS
under	IN	under IN PennPOS
development	NN	development NN PennPOS
for	IN	for c-acp NUPOS
treatment	NN	treatment NN PennPOS
of	IN	of pp-f NUPOS
fibrosis	NN	fibrosis NN PennPOS
.	.	. . NUPOS

A	DT	a dt NUPOS
First-in-Human	NN	First-in-Human NN PennPOS
(	(	( ( NUPOS
FIH	NN	FIH NN PennPOS
)	)	) ) NUPOS
trial	NN	trial NN PennPOS
was	VBD	be vbd NUPOS
performed	VBN	perform VBN PennPOS
to	TO	to p-acp NUPOS
assess	VB	assess VBP PennPOS
the	DT	the dt NUPOS
safety	NN	safety NN PennPOS
,	,	, , NUPOS
tolerability	NN	tolerability NN PennPOS
,	,	, , NUPOS
and	CC	and cc NUPOS
pharmacokinetics	NNS	pharmacokinetic NNS PennPOS
of	IN	of pp-f NUPOS
single	JJ	single JJ PennPOS
ascending	VBG	ascend vvg NUPOS
intravenous	JJ	intravenous JJ PennPOS
doses	NNS	dose NNS PennPOS
of	IN	of pp-f NUPOS
PRM-151	NN	PRM-151 NN PennPOS
administered	VBN	administer VBN PennPOS
to	TO	to p-acp NUPOS
healthy	JJ	healthy JJ PennPOS
subjects	NNS	subject NNS PennPOS
,	,	, , NUPOS
using	VBG	use VBG PennPOS
a	DT	a dt NUPOS
randomized	VBN	randomize VBN PennPOS
,	,	, , NUPOS
blinded	VBN	blind vvn NUPOS
,	,	, , NUPOS
placebo	NN	placebo NN PennPOS
controlled	JJ	controlled JJ PennPOS
study	NN	study NN PennPOS
design	NN	design NN PennPOS
.	.	. . NUPOS

Each	DT	each d NUPOS
cohort	NN	cohort NN PennPOS
included	VBD	include VBD PennPOS
three	CD	three crd NUPOS
healthy	JJ	healthy JJ PennPOS
subjects	NNS	subject NNS PennPOS
(	(	( ( NUPOS
PRM-151	NN	PRM-151 NN PennPOS
:	:	: : NUPOS
placebo	NN	placebo NN PennPOS
;	:	; : NUPOS
2:1	CD	2:1 CD PennPOS
)	)	) ) NUPOS
.	.	. . NUPOS

SAP	NN	sap NN PennPOS
levels	NNS	level NNS PennPOS
were	VBD	be vbd NUPOS
assessed	VBN	assess VBN PennPOS
using	VBG	use VBG PennPOS
a	DT	a dt NUPOS
validated	VBN	validate VBN PennPOS
ELISA	NN	elisa NN PennPOS
method	NN	method NN PennPOS
,	,	, , NUPOS
non-discriminating	JJ	non-discriminating JJ PennPOS
between	IN	between IN PennPOS
endogenous	JJ	endogenous JJ PennPOS
and	CC	and cc NUPOS
exogenous	JJ	exogenous JJ PennPOS
SAP	NN	sap NN PennPOS
.	.	. . NUPOS

At	IN	at pp NUPOS
a	DT	a dt NUPOS
dose	NN	dose NN PennPOS
level	NN	level NN PennPOS
of	IN	of pp-f NUPOS
10	CD	10 crd NUPOS
mg/kg	NN	mg/kg NN PennPOS
,	,	, , NUPOS
at	IN	at pp NUPOS
which	WDT	which r-crq NUPOS
a	DT	a dt NUPOS
physiologic	JJ	physiologic JJ PennPOS
plasma	NN	plasma NN PennPOS
level	NN	level NN PennPOS
of	IN	of pp-f NUPOS
SAP	NN	sap NN PennPOS
was	VBD	be vbd NUPOS
reached	VBN	reach VBN PennPOS
,	,	, , NUPOS
two	CD	two crd NUPOS
additional	JJ	additional JJ PennPOS
healthy	JJ	healthy JJ PennPOS
volunteers	NNS	volunteer NNS PennPOS
and	CC	and cc NUPOS
three	CD	three crd NUPOS
pulmonary	JJ	pulmonary JJ PennPOS
fibrosis	NN	fibrosis NN PennPOS
(	(	( ( NUPOS
PF	NN	pf NN PennPOS
)	)	) ) NUPOS
patients	NNS	patient NNS PennPOS
were	VBD	be vbd NUPOS
enrolled	VBN	enrol vvn NUPOS
enabling	VBG	enable VBG PennPOS
comparison	NN	comparison NN PennPOS
of	IN	of pp-f NUPOS
the	DT	the dt NUPOS
pharmacokinetic	JJ	pharmacokinetic JJ PennPOS
SAP	NN	sap NN PennPOS
profile	NN	profile NN PennPOS
between	IN	between IN PennPOS
healthy	JJ	healthy JJ PennPOS
volunteers	NNS	volunteer NNS PennPOS
and	CC	and cc NUPOS
PF	NN	pf NN PennPOS
patients	NNS	patient NNS PennPOS
.	.	. . NUPOS

In	IN	in IN PennPOS
addition	NN	addition NN PennPOS
,	,	, , NUPOS
the	DT	the dt NUPOS
percentage	NN	percentage NN PennPOS
of	IN	of pp-f NUPOS
fibrocytes	NNS	fibrocyte NNS PennPOS
(	(	( ( NUPOS
CD45	NN	CD45 NN PennPOS
+	CC	+ CC PennPOS
/	:	/ : NUPOS
Procollagen-1	NN	Procollagen-1 NN PennPOS
+	CC	+ CC PennPOS
cells	NNS	cell NNS PennPOS
)	)	) ) NUPOS
in	IN	in IN PennPOS
whole	JJ	whole JJ PennPOS
blood	NN	blood NN PennPOS
samples	NNS	sample NNS PennPOS
was	VBD	be vbd NUPOS
assessed	VBN	assess VBN PennPOS
to	TO	to p-acp NUPOS
demonstrate	VB	demonstrate VBP PennPOS
biological	JJ	biological JJ PennPOS
activity	NN	activity NN PennPOS
of	IN	of pp-f NUPOS
PRM-151	NN	PRM-151 NN PennPOS
in	IN	in IN PennPOS
the	DT	the dt NUPOS
target	NN	target NN PennPOS
population	NN	population NN PennPOS
.	.	. . NUPOS

PRM-151	NN	PRM-151 NN PennPOS
administration	NN	administration NN PennPOS
was	VBD	be vbd NUPOS
generally	RB	general av-j NUPOS
well	RB	well av NUPOS
tolerated	VBN	tolerate VBN PennPOS
.	.	. . NUPOS

In	IN	in IN PennPOS
two	CD	two crd NUPOS
pulmonary	JJ	pulmonary JJ PennPOS
fibrosis	NN	fibrosis NN PennPOS
patients	NNS	patient NNS PennPOS
non-specific	JJ	non-specific JJ PennPOS
,	,	, , NUPOS
transient	JJ	transient JJ PennPOS
skin	NN	skin NN PennPOS
reactions	NNS	reaction NNS PennPOS
(	(	( ( NUPOS
urticaria	NN	urticaria NN PennPOS
and	CC	and cc NUPOS
erythema	NN	erythema NN PennPOS
)	)	) ) NUPOS
were	VBD	be vbd NUPOS
observed	VBN	observe VBN PennPOS
.	.	. . NUPOS

PRM-151	NN	PRM-151 NN PennPOS
administration	NN	administration NN PennPOS
resulted	VBD	result VBD PennPOS
in	IN	in IN PennPOS
a	DT	a dt NUPOS
6-to	JJ	6-to JJ PennPOS
13-fold	RB	13-fold RB PennPOS
increase	VB	increase VBP PennPOS
in	IN	in IN PennPOS
mean	JJ	mean JJ PennPOS
baseline	NN	baseline NN PennPOS
plasma	NN	plasma NN PennPOS
SAP	NN	sap NN PennPOS
levels	NNS	level NNS PennPOS
at	IN	at pp NUPOS
dose	NN	dose NN PennPOS
levels	NNS	level NNS PennPOS
of	IN	of pp-f NUPOS
5	CD	5 crd NUPOS
,	,	, , NUPOS
10	CD	10 crd NUPOS
,	,	, , NUPOS
and	CC	and cc NUPOS
20	CD	20 crd NUPOS
mg/kg	NN	mg/kg NN PennPOS
.	.	. . NUPOS

The	DT	the dt NUPOS
estimated	VBN	estimate VBN PennPOS
t1/2	NN	t1/2 NN PennPOS
of	IN	of pp-f NUPOS
PRM-151	NN	PRM-151 NN PennPOS
in	IN	in IN PennPOS
healthy	JJ	healthy JJ PennPOS
volunteers	NNS	volunteer NNS PennPOS
was	VBD	be vbd NUPOS
30	CD	30 crd NUPOS
h.	NN	H. np1 NUPOS
Pharmacokinetic	JJ	pharmacokinetic JJ PennPOS
profiles	NNS	profile NNS PennPOS
were	VBD	be vbd NUPOS
comparable	JJ	comparable JJ PennPOS
between	IN	between IN PennPOS
healthy	JJ	healthy JJ PennPOS
volunteers	NNS	volunteer NNS PennPOS
and	CC	and cc NUPOS
PF	NN	pf NN PennPOS
patients	NNS	patient NNS PennPOS
.	.	. . NUPOS

PRM-151	NN	PRM-151 NN PennPOS
administration	NN	administration NN PennPOS
resulted	VBD	result VBD PennPOS
in	IN	in IN PennPOS
a	DT	a dt NUPOS
30-50	CD	30-50 CD PennPOS
%	NN	% NN PennPOS
decrease	NN	decrease NN PennPOS
in	IN	in IN PennPOS
fibrocyte	JJ	fibrocyte JJ PennPOS
numbers	NNS	number NNS PennPOS
24	CD	24 crd NUPOS
h	NN	h NN PennPOS
post-dose	NN	post-dose NN PennPOS
.	.	. . NUPOS

This	DT	this d NUPOS
suggests	VBZ	suggest VBZ PennPOS
that	IN	that cst NUPOS
administration	NN	administration NN PennPOS
of	IN	of pp-f NUPOS
PRM-151	NN	PRM-151 NN PennPOS
may	MD	may vmb NUPOS
be	VB	be vbi NUPOS
associated	VBN	associate VBN PennPOS
with	IN	with pp NUPOS
a	DT	a dt NUPOS
reduction	NN	reduction NN PennPOS
of	IN	of pp-f NUPOS
fibrocytes	NNS	fibrocyte NNS PennPOS
in	IN	in IN PennPOS
PF	NN	pf NN PennPOS
patients	NNS	patient NNS PennPOS
,	,	, , NUPOS
a	DT	a dt NUPOS
population	NN	population NN PennPOS
for	IN	for c-acp NUPOS
which	WDT	which r-crq NUPOS
current	JJ	current JJ PennPOS
pharmacotherapeutic	JJ	pharmacotherapeutic JJ PennPOS
options	NNS	option NNS PennPOS
are	VBP	be vbb NUPOS
limited	VBN	limit VBN PennPOS
.	.	. . NUPOS

The	DT	the dt NUPOS
pharmacological	JJ	pharmacological JJ PennPOS
action	NN	action NN PennPOS
of	IN	of pp-f NUPOS
PRM-151	NN	PRM-151 NN PennPOS
should	MD	shall vmd NUPOS
be	VB	be vbi NUPOS
confirmed	VBN	confirm VBN PennPOS
in	IN	in IN PennPOS
future	JJ	future JJ PennPOS
research	NN	research NN PennPOS
.	.	. . NUPOS

